Rohtesh S. Mehta

7.1k total citations · 1 hit paper
135 papers, 2.1k citations indexed

About

Rohtesh S. Mehta is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Rohtesh S. Mehta has authored 135 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Hematology, 31 papers in Oncology and 25 papers in Immunology. Recurrent topics in Rohtesh S. Mehta's work include Hematopoietic Stem Cell Transplantation (61 papers), Acute Myeloid Leukemia Research (35 papers) and Immune Cell Function and Interaction (22 papers). Rohtesh S. Mehta is often cited by papers focused on Hematopoietic Stem Cell Transplantation (61 papers), Acute Myeloid Leukemia Research (35 papers) and Immune Cell Function and Interaction (22 papers). Rohtesh S. Mehta collaborates with scholars based in United States, South Africa and United Kingdom. Rohtesh S. Mehta's co-authors include Katayoun Rezvani, Elizabeth J. Shpall, Amin M. Alousi, Roy E. Smith, Marcin Chwistek, Richard E. Champlin, Partow Kebriaei, Michael Levy, Uday Popat and James M. Reuben and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Rohtesh S. Mehta

123 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Liposomal Amphotericin B for the Treatment of Systemic Fungal Infections in Patients with Cancer: A Preliminary Study

1985 329 citations Rohtesh S. Mehta et al. profile →

Peers

Countries citing papers authored by Rohtesh S. Mehta

Since Specialization

Citations

This map shows the geographic impact of Rohtesh S. Mehta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rohtesh S. Mehta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rohtesh S. Mehta more than expected).

Fields of papers citing papers by Rohtesh S. Mehta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rohtesh S. Mehta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rohtesh S. Mehta. The network helps show where Rohtesh S. Mehta may publish in the future.

Co-authorship network of co-authors of Rohtesh S. Mehta

This figure shows the co-authorship network connecting the top 25 collaborators of Rohtesh S. Mehta. A scholar is included among the top collaborators of Rohtesh S. Mehta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rohtesh S. Mehta. Rohtesh S. Mehta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Modeling donor age and type trade-offs for personalized selection in allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide prophylaxis 2026 ·Leukemia ·Rohtesh S. Mehta, (unknown), (unknown), Gabriela Rondón, Warren Fingrut, (unknown), (unknown), Amanda Olson, (unknown), (unknown)	0
2	Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide vs Conventional Prophylaxis 2025 ·JAMA Oncology ·Rohtesh S. Mehta, Rodney Sparapani, Christopher G. Kanakry, Shannon R. McCurdy, Jennifer N. Saultz, Aleksandr Lazaryan, Filippo Milano, S J Lee	2
3	Impact of Donor Age and Donor Cytomegalovirus Serostatus on Outcomes After Related Donor Allogeneic Hematopoietic Stem Cell Transplantation 2025 ·American Journal of Hematology ·Rohtesh S. Mehta, Hannah Choe, Jennifer N. Saultz, (unknown), Prashant Sharma, Taha Al‐Juhaishi, (unknown), Aleksandr Lazaryan, Anurag K. Singh, Elisabetta Xue, Dimana Dimitrova, (unknown), Shannon R. McCurdy, Annie Im, (unknown), (unknown), Jennifer A. Kanakry, Filippo Milano, Christopher G. Kanakry	0
4	The Impact of Isolated HLA-DQB1 Mismatch and Donor Age in Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide 2025 ·Transplantation and Cellular Therapy ·Rohtesh S. Mehta, Yosra Aljawai, Partow Kebriaei, Amanda Olson, Betül Oran, Gabriela Rondón, Katayoun Rezvani, R. Champlin, (unknown)	1
5	Outcomes of haploidentical vs mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxis 2025 ·Blood Advances ·Yosra Aljawai, Jeremy Ramdial, Gabriela Rondón, (unknown), Partow Kebriaei, Uday Popat, Betül Oran, Katayoun Rezvani, Richard E. Champlin, Elizabeth J. Shpall, Rohtesh S. Mehta	2
6	Long-term outcomes and quality of life with treosulfan-based conditioning in hematological malignancies 2025 ·Blood Advances ·Rohtesh S. Mehta, Stephanie J. Lee, Ted Gooley, (unknown), Ann Dahlberg, Colleen Delaney, Boglarka Gyurkocza, (unknown), H. Joachim Deeg, Filippo Milano	0
7	Steroid Refractory Acute GVHD: The Hope for a Better Tomorrow 2025 ·American Journal of Hematology ·(unknown), Rohtesh S. Mehta, Amin M. Alousi	3
8	Role of Donor Cytomegalovirus Serostatus in Cytomegalovirus-Seronegative Recipients of Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Prophylaxis 2025 ·Transplantation and Cellular Therapy ·Rohtesh S. Mehta, Yosra Aljawai, Taha Al‐Juhaishi, Jennifer N. Saultz, Filippo Milano, Jennifer A. Kanakry, Christopher G. Kanakry, Aleksandr Lazaryan	1
9	SOHO State of the Art Updates and Next Questions \| Current Status and Future Directions of Donor Selection 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Rohtesh S. Mehta	2
10	Decreasing chronic graft-versus-host disease rates in all populations 2024 ·Blood Advances ·Paul A. Carpenter, Theodore A. Gooley, (unknown), Catherine J. Lee, Lauri Burroughs, Rohtesh S. Mehta, Rachel B. Salit, Neel S. Bhatt, Elizabeth F. Krakow, Ann Dahlberg, Albert C. Yeh, Corinne Summers, Masumi Ueda, Effie W. Petersdorf, (unknown), Laura Connelly‐Smith, Stephanie J. Lee	6
11	Interplay between donor age and HLA-DP matching in 10/10 HLA-matched unrelated donor HCT 2024 ·Blood Advances ·Rohtesh S. Mehta, Effie W. Petersdorf, Tao Wang, Stephen R. Spellman, Stephanie J. Lee	2
12	Haploidentical Versus Mismatched Unrelated Donor Hematopoietic Cell Transplantation: HLA Factors and Donor Age Considerations 2024 ·Transplantation and Cellular Therapy ·Rohtesh S. Mehta, Effie W. Petersdorf, Tao Wang, Stephanie J. Lee	6
13	Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host disease 2024 ·Bone Marrow Transplantation ·(unknown), Amin M. Alousi, Jin S. Im, LaQuisa Hill, (unknown), Uday Popat, Chitra Hosing, Partow Kebriaei, Amanda Olson, Rohtesh S. Mehta, George Chen, Muzaffar H. Qazilbash, Elizabeth J. Shpall, Richard E. Champlin, Rima M. Saliba	1
14	A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement 2023 ·Bone Marrow Transplantation ·Rohtesh S. Mehta, Haris Ali, (unknown), (unknown), (unknown), Voravit Ratanatharathorn, Saar Gill, Gèrard Socié, Kevin Anderson, J Cahn, (unknown), Richard E. Champlin, Elizabeth J. Shpall, Shernan G. Holtan, Amin M. Alousi	5
15	Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation 2023 ·Blood Advances ·Nicholas J. Short, (unknown), Farhad Ravandi, Graciela M. Nogueras‐González, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo, Marina Konopleva, Gautam Borthakur, Betül Oran, Gheath Alatrash, Rohtesh S. Mehta, Elias Jabbour, Musa Yılmaz, Ghayas C. Issa, Abhishek Maiti, Richard E. Champlin, Hagop M. Kantarjian, Elizabeth J. Shpall, Uday Popat	13
16	Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type 2023 ·Blood Advances ·Rohtesh S. Mehta, (unknown), Amin M. Alousi, Christopher G. Kanakry, Richard E. Champlin, Katayoun Rezvani, Elizabeth J. Shpall, Kristin Page, Shahinaz M. Gadalla, Daniel J. Weisdorf, Partow Kebriaei	13
17	Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification 2022 ·American Journal of Hematology ·Patrick K. Reville, Koji Sasaki, Hagop M. Kantarjian, Naval Daver, Musa Yılmaz, Courtney D. DiNardo, Nicholas J. Short, Gautam Borthakur, Naveen Pemmaraju, Rohtesh S. Mehta, Sherry Pierce, Sergej Konoplev, Joseph D. Khoury, Guillermo Garcia‐Manero, Marina Konopleva, Elias Jabbour, Farhad Ravandi, Tapan M. Kadia	16
18	Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations 2020 ·American Journal of Hematology ·Curtis A. Lachowiez, Sarah A. Bannon, Sanam Loghavi, Feng Wang, Rashmi Kanagal‐Shamanna, Rohtesh S. Mehta, Naval Daver, Gautam Borthakur, Naveen Pemmaraju, Farhad Ravandi, Keyur P. Patel, Guillermo Garcia‐Manero, Koichi Takahashi, Hagop M. Kantarjian, Kapil N. Bhalla, Courtney D. DiNardo	3
19	Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors 2020 ·Cancer ·Betül Oran, Guillermo Garcia‐Manero, Rima M. Saliba, Mansour Alfayez, Gheath Alatrash, Stefan O. Ciurea, Elias Jabbour, Rohtesh S. Mehta, Uday Popat, Farhad Ravandi, Amin M. Alousi, Tapan M. Kadia, Marina Konopleva, Courtney D. DiNardo, Katy Rezvani, Elizabeth J. Shpall, Padmanee Sharma, Hagop M. Kantarjian, Richard E. Champlin, Naval Daver	31
20	Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia 2018 ·Biology of Blood and Marrow Transplantation ·(unknown), Katayoun Rezvani, Betül Oran, Rohtesh S. Mehta, Gabriela Rondón, Partow Kebriaei, Uday Popat, Yago Nieto, Chitra Hosing, Muzaffar H. Qazilbash, Issa F. Khouri, Elizabeth J. Shpall, Richard E. Champlin, David Marín	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact